Syncytial cells, nuclear clearing, and psammoma bodies are common histological features in meningiomas, yet present differently in subtypes [11]. Although immunochemistry markers such as cytokeratin 18 (CK18), somatostatin receptor 2A (SSTR2A), and epithelial membrane antigen (EMA) can confirm a meningioma, the variable expressivity among subtypes makes immunotherapies challenging for treating meningiomas [11]. This evidence concerns the gene KRT18 and meningioma.